These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32617667)

  • 41. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
    Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
    Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A Case of Simultaneous Multiple Gastric Cancers Showing Differences of Response after Neoadjuvant Chemotherapy with Docetaxel, CDDP, and S-1].
    Sakai T; Ichikawa H; Ishikawa T; Kosugi S; Hanyu T; Usui K; Muneoka Y; Otani T; Hishiki M; Nagahashi M; Sakata J; Kobayashi T; Kameyama H; Wakai T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2377-2379. PubMed ID: 28133327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Dissection after Neoadjuvant Chemotherapy].
    Ogawa T; Choda Y; Ninomiya M; Nagai Y; Mimura N; Miyake S; Ishida M; Matsukawa H; Ojima Y; Idani H; Shiozaki S; Okajima M
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2205-2207. PubMed ID: 28133270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant chemotherapy in controlling lymph node metastasis for locally advanced gastric cancer in a Chinese population.
    Dong S; Yu JR; Zhang Q; Liu XS
    J Chemother; 2016; 28(1):59-64. PubMed ID: 25977986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
    Tai Q; Shao H; Liu Y; Li E; Zhao R
    J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
    Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
    Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
    Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
    Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.
    Yamada Y; Boku N; Mizusawa J; Iwasa S; Kadowaki S; Nakayama N; Azuma M; Sakamoto T; Shitara K; Tamura T; Chin K; Hata H; Nakamori M; Hara H; Yasui H; Katayama H; Fukuda H; Yoshikawa T; Sasako M; Terashima M
    Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):501-510. PubMed ID: 31101534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
    Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
    Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002.
    Katayama H; Ito S; Sano T; Takahari D; Mizusawa J; Boku N; Tsuburaya A; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2012 Jun; 42(6):556-9. PubMed ID: 22525210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Evaluation of TS-1 combined with cisplatin for neoadjuvant chemotherapy in patients with advanced gastric cancer].
    Yabusaki H; Nashimoto A; Tanaka O
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1933-40. PubMed ID: 14650962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
    Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
    Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A patient with advanced gastric cancer who responded to neoadjuvant S-1 plus cisplatin chemotherapy].
    Tanaka H; Doi K; Ogata K; Inoue K; Sugiyama S; Iwatsuki M; Furuhashi S; Ogawa K; Takamori H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2207-9. PubMed ID: 24394061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?
    Zhang J; Zou S; Luo R; Zhu Z; Wang Z; Xu H; Huang B
    Clin Transl Oncol; 2019 Dec; 21(12):1699-1706. PubMed ID: 30977046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective randomized controlled trial to compare laparoscopic distal gastrectomy (D2 lymphadenectomy plus complete mesogastrium excision, D2 + CME) with conventional D2 lymphadenectomy for locally advanced gastric adenocarcinoma: study protocol for a randomized controlled trial.
    Shen J; Cao B; Wang Y; Xiao A; Qin J; Wu J; Yan Q; Hu Y; Yang C; Cao Z; Hu J; Yin P; Xie D; Gong J
    Trials; 2018 Aug; 19(1):432. PubMed ID: 30092843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A Case of Resected Advanced Gastric Cancer Exhibiting Pathological Complete Response after Neoadjuvant Che-motherapy(DTX/CDDP/S-1:DCS)].
    Suzuki Y; Kunisaki C; Tsuburaya A; Ohshima T; Yukawa N; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2046-8. PubMed ID: 26805259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.